please wait

EMIM 2016 - Session Details

PS 17 | Antibodies, Nanoparticles, Small Molecules | Diagnosis and Therapy in Oncology
Type: Parallel Session
Chair:  Joanna Napp, Tony Lahoutte
Date: March 10, 2016
Time: 13:30 - 15:00
Room: Mission 1
#PS 17 / IL Antibodies, Nanoparticles and Small Molecules for Diagnosis and Therapy in Oncology (#568)
Jan Grimm 1,2,3
1Memorial Sloan Kettering Cancer Center Molecular Pharmacology, 1275 York Avenue, New York, NY 10065, United States
2Memorial Sloan Kettering Cancer Center Radiology, 1275 York Avenue, New York, NY 10065, United States
3Weil Cornell Medical College Pharmacology, 1300 York Avenue, New York, NY 10065, United States
#PS 17 / 1 Quantitative Pharmacokinetic PET Imaging of a T Cell-Dependent Bispecific Diabody for the Treatment of Solid Tumors (#308)
Friederike Braun 1, Shruthi Prasad 2, Simone Gaedicke 2, Gabriele Niedermann 2
1University of Freiburg Dept. of Nuclear Medicine, Hugstetter Str. 49, 79106 Freiburg, Germany
2University of Freiburg Dept. of Radiation Oncology, Robert-Koch-Str. 3, 79106 Freiburg, Germany
#PS 17 / 2 Imaging and selective elimination of glioblastoma stem cells with theranostic near-infrared-labeled CD133-specific antibodies (#136)
Hua Jing 1,2, Claudia Weidensteiner 3, Wilfried Reichardt 3, Xuekai Zhu 1, Hisataka Kobayashi 4, Gabriele Niedermann 1,2
1Dept. for Radiation Oncology University Hospital Freiburg, Robert-koch str. 3, D-79106 Freiburg, Germany
2Cancer Consortium (DKTK) German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 280, D-69121 Heidelberg, Germany
3Radiology Medical Physics University Hospital Freiburg, Breisacher Straße 60a, D-79106 Freiburg, Germany
4Molecular Imaging Program, Center for Cancer Research, National Cancer Institute National Institutes of Health, National Cancer Institute Building 10, Room B3B69F, Bethesda, MD 20892, United States
#PS 17 / 3 Preclinical imaging study using 149Tb-DOTANOC – Promising features of 149Tb for theragnostics combining α-therapy and PET (#475)
Nicholas van der Meulen 1,2, Christiaan Vermeulen 2, Ulli Koester 3, Karl Johnston 4, Roger Schibli 2, Andreas Tuerler 1, Cristina Mueller 2
1Paul Scherrer Institute Laboratory of Radiochemistry, 5232 Villigen-PSI, Switzerland
2Paul Scherrer Institute Center of Radiopharmaceutical Sciences, 5232 Villigen-PSI, Switzerland
3Institut Laue-Langevin, Grenoble, France
4CERN ISOLDE, Geneva, Switzerland
#PS 17 / 4 Selection of a lead anti-CD20 nanobody as a theranostic tool for targeted radionuclide therapy of Non-Hodgkin Lymphoma (#358)
Ahmet Krasniqi 1, Milcah Kahkelam Bungwa 1, Catarina Xavier 1, Serge Muyldermans 2, Tony Lahoutte 1,3, Jan Tavernier 4, Matthias D'huyvetter 1, Nick Devoogdt 1
1Vrije Universiteit Brussel (VUB) In Vivo Cellular and Molecular Imaging (ICMI) Laboratory (ICMI), Laarbeeklaan 103, 1090 Brussels, Belgium
2Vrije Universiteit Brussel (VUB) Laboratory of Cellular and Molecular Immunology, pleinlaan 2, 1050 Brussels, Belgium
3University Hospital Brussels (UZ Brussel) Nuclear Medicine, laarbeeklaan 101, 1090 Brussels, Belgium
4Ghent University Cytokine Receptor Laboratory, Albert Baertsoenkaai 3, 9000 Ghent, Belgium
#PS 17 / 5 Non-invasive in vivo PET imaging of senescence in a GEPIRshp53pWZLHras xenograft mouse model (#306)
Kuehn Anna1, Cotton Jonathan1, Fuchs Kerstin1, Maurer Andreas1, Wolter Katharina2, Schulze-Osthoff Klaus3, Zender Lars2, Pichler Bernd J.1
1Eberhard Karls University of Tuebingen, Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy - Tuebingen, Germany
2Eberhard Karls University of Tuebingen, Division of Molecular Oncology of Solid Tumors, Department of Internal Medicine I - Tuebingen, Germany
3Eberhard Karls University of Tuebingen, Interfaculty Institute of Biochemistry - Tuebingen, Germany


  back to overview

conwerk® - © 2016 EventClass GmbH